Clinical Trial Update: BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease [Phase 3]

View source ↗

Summary

Phase 3 trial comparing BGB-43395 plus letrozole to a CDK4/6 inhibitor plus letrozole in first-line, advanced or metastatic HR+/HER2- breast cancer; the study i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• BGB-43395
• CDK4/6 inhibitor (unspecified)
• Letrozole (letrozole)

Snippet

Sponsor: BeOne Medicines | Conditions: HR+/HER2- Breast Cancer | Phase 3 | Status: NOT_YET_RECRUITING